SOFOSBUVIRA in English translation

• sofosbuvir

Examples of using Sofosbuvira in Croatian and their translations into English

su podaci o primjeni ledipasvira, sofosbuvira ili lijeka Harvoni u trudnica ograničeni manje od 300 trudnoća.
limited amount of data(less than 300 pregnancy outcomes) from the use of ledipasvir, sofosbuvir or Harvoni in pregnant women.

Očekuje se da će istovremena primjena lijeka Harvoni s okskarbazepinom smanjiti koncentraciju ledipasvira i sofosbuvira i tako dovestido smanjenog terapijskog učinka lijeka Harvoni.
Co-administration of Harvoni with oxcarbazepine is expected to decrease the concentration of ledipasvir and sofosbuvir leading to reduced therapeutic effect of Harvoni.

Lijek Daklinza treba koristiti u kombinaciji s drugim lijekovima za liječenje kroničnog hepatitisa C, poput sofosbuvira, peginterferona alfa i ribavirina.
Daklinza must be used in combination with other medicines for chronic hepatitis C, such as sofosbuvir, peginterferon alfa and ribavirin.

Lijek Epclusa dostupan je u obliku tableta koje sadrže 400 mg sofosbuvira i 100 mg velpatasvira.
Epclusa is available as tablets which contain 400 mg sofosbuvir and 100 mg velpatasvir.

Za prethodno liječene bolesnike s infekcijom genotipom 1 HCV-a ne postoje podaci za kombinaciju sofosbuvira, peginterferona i ribavirina.
For previously treated patients with genotype 1 HCV infection, no data exists with the combination of sofosbuvir, peginterferon alfa and ribavirin.

farmakokinetike istodobno primijenjenog lijeka sa/bez sofosbuvira i srednja vrijednost omjera sofosbuvira i GS-331007 sa/bez istodobno primijenjenog lijeka.
of co-administered drug pharmacokinetics with/without sofosbuvir and mean ratio of sofosbuvir and GS-331007 with/without co-administered drug.

Procjena sofosbuvira u kombinaciji s velpatasvirom nije pokazala nikakav antagonistički učinak u smanjenju razina HCV RNK u stanicama replikona.
Evaluation of sofosbuvir in combination with velpatasvir showed no antagonistic effect in reducing HCV RNA levels in replicon cells.

Hemodijalizom se može učinkovito odstraniti glavni cirkulirajući metabolit sofosbuvira, GS-331007, uz omjer ekstrakcije od 53.
Haemodialysis can efficiently remove the predominant circulating metabolite of sofosbuvir, GS-331007, with an extraction ratio of 53.

Nisu utvrđene nikakve klinički relevantne razlike u farmakokinetici sofosbuvira, GS-331007 ili velpatasvira kojima bi uzrok bila rasa ili spol.
No clinically relevant pharmacokinetic differences due to race or gender have been identified for sofosbuvir, GS-331007 or velpatasvir.

Nisu bili opaženi teratogeni učinci sofosbuvira u ispitivanjima njegove razvojne toksičnosti na štakorima i kunićima.
No teratogenic effects were observed in the rat and rabbit developmental toxicity studies with sofosbuvir.

Vrijednosti 50% učinkovite koncentracije(EC50) sofosbuvira i velpatasvira protiv replikona pune duljine ili kimeričkih replikona koji kodiraju sekvence NS5B
The 50% effective concentration(EC50) values of sofosbuvir and velpatasvir against full-length or chimeric replicons encoding NS5B

Linearnost doze sofosbuvira i njegovog primarnog metabolita,
The dose linearity of sofosbuvir and its primary metabolite,

Najviše zabilježene doze sofosbuvira i velpatasvira bile su jedna doza od 1200 mg odnosno jedna doza od 500 mg.
The highest documented doses of sofosbuvir and velpatasvir were a single dose of 1,200 mg and a single dose of 500 mg, respectively.

Srednja vrijednost ± SD EC50 sofosbuvira za kimerične replikone koji kodiraju sekvence NS5B iz kliničkih izolata iznosila je 0, 068 ± 0, 024 μM za genotip 1a n 67.
The mean± SD EC50 of sofosbuvir against chimeric replicons encoding NS5B sequences from clinical isolates was 0.068± 0.024 μM for genotype 1a n 67.

Farmakokinetika sofosbuvira i GS-331007 u pedijatrijskih ispitanika nisu ustanovljene vidjeti dio 4.2.
The pharmacokinetics of sofosbuvir and GS-331007 in paediatric subjects have not been established see section 4.2.

Prisutnost 40% ljudskog seruma nije imala učinka na anti-HCV djelovanje sofosbuvira, ali je smanjila anti-HCV djelovanje ledipasvira 12 puta protiv replikona genotipa 1a HCV-a.
The presence of 40% human serum had no effect on the anti-HCV activity of sofosbuvir but reduced the anti-HCV activity of ledipasvir by 12-fold against genotype 1a HCV replicons.

Sigurnost i djelotvornost sofosbuvira nisu ustanovljene u pacijenata s teškim oštećenjem bubrega ili završnim stadijem bolesti bubrega.
The safety and efficacy of sofosbuvir have not been established in patients with severe renal impairment or ESRD.

Ove se preporuke temelje na kinetici apsorpcije sofosbuvira i GS-331007 koja pokazuje da se većina doze apsorbira u roku od 2 sata nakon primjene.
These recommendations are based on the absorption kinetics of sofosbuvir and GS-331007 suggesting that the majority of the dose is absorbed within 2 hours after dosing.

Dostupni farmakokinetički podaci u životinja pokazuju da se ledipasvir i metaboliti sofosbuvira izlučuju u mlijeku vidjeti dio 5.3.
Available pharmacokinetic data in animals has shown excretion of ledipasvir and metabolites of sofosbuvir in milk see section 5.3.

Dostupni farmakokinetički podaci u životinja pokazuju da se velpatasvir i metaboliti sofosbuvira izlučuju u mlijeku.
Available pharmacokinetic data in animals have shown excretion of velpatasvir and metabolites of sofosbuvir in milk.